FDA approves risdiplam for spinal muscular atrophy in adults and children

Approval for this mRNA splicing modifier is based on data from two phase III studies; FIREFISH in symptomatic infants aged 2 to 7 months and SUNFISH in children and adults aged 2 to 25 years; both demonstrated clinically-meaningful improvements in motor function.


Biospace Inc.